Effects of cidofovir treatment on cytokine induction in murine models of cowpox and vaccinia virus infection

Antiviral Research

Volumn 72, Issue 2, 2006, Pages 125-133

  Knorr, Corinna W ^a   Allen, Stanley D ^a   Torres, Anthony R ^a   Smee, Donald F ^a  

^a UTAH STATE UNIVERSITY   (United States)

Author keywords

Antiviral; Cidofovir; Cowpox; Cytokines; Orthopoxvirus; Vaccinia

Indexed keywords

CIDOFOVIR; CYTOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 10; INTERLEUKIN 11; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1; MACROPHAGE INFLAMMATORY PROTEIN 1GAMMA; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 3; MONOCYTE CHEMOTACTIC PROTEIN 5; PLACEBO; TISSUE INHIBITOR OF METALLOPROTEINASE 1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; COWPOX VIRUS; CYTOKINE PRODUCTION; DISEASE MODEL; DOSE TIME EFFECT RELATION; FEMALE; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; STRAIN IDENTIFICATION; VACCINIA VIRUS; VIRUS INFECTION;

ANIMALS; ANTIVIRAL AGENTS; COWPOX; CYTOKINES; CYTOSINE; DISEASE MODELS, ANIMAL; FEMALE; LUNG; MICE; MICE, INBRED BALB C; PHOSPHONIC ACIDS; VACCINIA; VACCINIA VIRUS;

ANIMALIA; COWPOX VIRUS; MURINAE; ORTHOPOXVIRUS; VACCINIA VIRUS;

EID: 33748307377     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antiviral.2006.05.005     Document Type: Article

References (41)

1. Alcamí A., Symons J.A., Collins P.D., Williams T.J., and Smith G.L. Blockade of chemokine activity by a soluble chemokine binding protein from vaccinia virus. J. Immunol. 160 (1998) 624-633
2. Amichay D., Gazzinelli R.T., Karupiah G., Moench T.R., Sher A., and Farber J.M. Genes for chemokines MuMig and Crg-2 are induced in protozoan and viral infections in response to IFN-γ with patterns of tissue expression that suggest nonredundant roles in vivo. J. Immunol. 157 (1996) 4511-4520
3. Biron C.A., and Sen G.C. Interferons and other cytokines. In: Knipe D.M., and Howley P.M. (Eds). Fundamental Virology. 4th ed. (2001), Lippincott Williams & Wilkins, Philadelphia 321-351
4. Bonecchi R., Bianchi G., Bordignon P.P., D'Ambrosio D., Lang R., Borsatti A., Sozzani S., Allavena P., Gray P.A., Manotvani A., and Sinigaglia F. Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. J. Exp. Med. 187 (1998) 129-134
5. Bray M., Martinez M., Smee D.F., Kefauver D., Thompson E., and Huggins J.W. Cidofovir protects mice against lethal aerosol or intranasal cowpox virus challenge. J. Infect. Dis. 181 (2000) 10-19
6. Carpenter E.A., Ruby J., and Ramshaw I.A. IFN-γ, TNF, and IL-6 production by vaccinia virus immune spleen cells: an in vitro study. J. Immunol. 152 (1994) 2652-2659
7. Chaudhri G., Panchanathan V., Buller R.M.L., van den Eertwegh A.J.M., Claassen E., Zhou J., de Chazal R., Laman J.D., and Karupiah G. Polarized type 1 cytokine response and cell-mediated immunity determine genetic resistance to mousepox. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 9057-9062
8. Crotty S., Felgner P., Davies H., Glidewell J., Villarreal L., and Ahmed R. Long-term B cell memory in humans after smallpox vaccination. J. Immunol. 171 (2003) 4969-4973
9. De Maeyer E., and De Maeyer-Guignard J. Interferons. In: Thomson A. (Ed). The Cytokine Handbook. 3rd ed. (1998), Academic Press, San Diego 491-516
10. Flexner C., Hügin A., and Moss B. Prevention of vaccinia virus infection in immunodeficient mice by vector-directed IL-2 expression. Nature 330 (1987) 259-262
11. Gu L., Tseng S., Horner R.M., Tam C., Loda M., and Rollins B.J. Control of Th2 polarization by the chemokine monocyte chemoattractant protein-1. Nature 404 (2000) 407-411
12. Hammarlund E., Lewis M.W., Hansen S.G., Strelow L.I., Nelson J.A., Sexton G.J., Hanifin J.M., and Slifka M.K. Duration of antiviral immunity after smallpox vaccination. Nat. Med. 9 (2003) 1131-1137
13. Hirano T. Interleukin-6. In: Thomson A. (Ed). The Cytokine Handbook. 3rd ed. (1998), Academic Press, San Diego 197-228
14. Hooper J.W., Thompson E., Wilhelmsen C., Zimmerman M., Ait Ichou M., Steffen S.E., Schmaljohn C.S., Schmaljohn A.L., and Jahrling P.B. Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox. J. Virol. 78 (2004) 4433-4443
15. Jackson R.J., Ramsay A.J., Christensen C.D., Beaton S., Hall D.F., and Ramshaw I.A. Expression of mouse interleukin-4 by a recombinant ectromelia virus suppresses cytolytic lymphocyte responses and overcomes genetic resistance to mousepox. J. Virol. 75 (2001) 1205-1210
16. Jahrling P.B., Hensley L.E., Martinez M.J., LeDuc J.W., Rubins K.H., Relman D.A., and Huggins J.W. Exploring the potential of variola virus infection of cynomolgus macaques as a model for human smallpox. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 15196-15200
17. Karpus W.J., Lukacs N.W., Kennedy K.J., Smith W.S., Hurst S.D., and Barrett T.A. Differential CC chemokine-induced enhancement of T helper cytokine production. J. Immunol. 158 (1997) 4129-4136
18. Learned L.A., Reynolds M.G., Wassa D.W., Li Y., Olson V.A., Karem K., Stempora L.L., Braden Z.H., Kline R., Likos A., Libama F., Moudzeo H., Bolanda J.D., Tarangonia P., Boumandoki P., Formenty P., Harvey J.M., and Damon I.K. Extended interhuman transmission of monkeypox in a hospital community in the Republic of the Congo, 2003. Am. J. Trop. Med. Hyg. 73 (2005) 428-434
19. Liu G., Zhai Q., Schaffner D.J., Wu A., Yohannes A., Robinson T.M., Maland M., Wells J., Voss T.G., Bailey C., and Alibek K. Prevention of lethal respiratory vaccinia infections in mice with interferon-α and interferon-γ. FEMS Immunol. Med. Microbiol. 40 (2004) 201-206
20. Mahalingam S., Farber J.M., and Karupiah G. The interferon-inducible chemokines MuMig and Crg-2 exhibit antiviral activity in vivo. J. Virol. 73 (1999) 1479-1491
21. Mahalingam S., and Karupiah G. Expression of the interferon-inducible chemokines MuMig and Crg-2 following vaccinia virus infection in vivo. Immunol. Cell Biol. 78 (2000) 156-160
22. Proost P., Wuyts A., Opdenakker G., and Van Damme J. Monocyte chemotactic proteins 1, 2 and 3. In: Mire-Sluis A.R., and Thorpe R. (Eds). Cytokines (1998), Academic Press, San Diego 489-506
23. Quenelle D.C., Collins D.J., and Kern E.R. Efficacy of multiple- or single-dose cidofovir against vaccinia and cowpox virus infections in mice. Antimicrob. Agents Chemother. 47 (2003) 3275-3280
24. Ramshaw I.A., Andrew M.E., Phillips S.M., Boyle D.B., and Coupar B.E.H. Recovery of immunodeficient mice from a vaccinia virus/IL-2 recombinant infection. Nature 329 (1987) 545-546
25. Ramshaw I.A., Ramsay A.J., Karupiah G., Rolph M.S., Mahalingam S., and Ruby J.C. Cytokines and immunity to viral infections. Immunol. Rev. 159 (1997) 119-135
26. Reading P.C., and Smith G.L. A kinetic analysis of immune mediators in the lungs of mice infected with vaccinia virus and comparison with intradermal infection. J. Gen. Virol. 84 (2003) 1973-1983
27. Reading P.C., and Smith G.L. Vaccinia virus interleukin-18-binding protein promotes virulence by reducing gamma interferon production and natural killer and T-cell activity. J. Virol. 77 (2003) 9960-9968
28. Rees D.G.C., Gates A.J., Green M., Eastaugh L., Lukaszewski R.A., Griffin K.F., Krieg A.M., and Titball R.W. CpG-DNA protects against a lethal orthopoxvirus infection in a murine model. Antiviral Res. 65 (2005) 87-95
29. Robbins S.J., Jackson R.J., Fenner F., Beaton S., Medveczky J., Ramshaw I.A., and Ramsay A.J. The efficacy of cidofovir treatment of mice infected with ectromelia (mousepox) virus encoding interleukin-4. Antiviral Res. 66 (2005) 1-7
30. Rock M.T., Yoder S.M., Talbot T.R., Edwards K.M., and Crowe Jr. J.E. Adverse events after smallpox immunizations are associated with alterations in systemic cytokine levels. J. Infect. Dis. 189 (2004) 1401-1410
31. Rokita H., Kupiec T., Guzik K., and Koj A. Vaccinia virus-regulated acute phase cytokine production in human fibroblasts, U937 cells and endothelium. Mediators Inflamm. 7 (1998) 73-78
32. Sallusto F., Lenig D., Mackay C.R., and Lanzavecchia A. Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes. J. Exp. Med. 187 (1998) 875-883
33. Sharma D.P., Ramsay A.J., Maguire D.J., Rolph M.S., and Ramshaw I.A. Interleukin-4 mediates down regulation of antiviral cytokine expression and cytotoxic T-lymphocyte responses and exacerbates vaccinia virus infection in vivo. J. Virol. 70 (1996) 7103-7707
34. Siveke J.T., and Hamann A. T helper 1 and T helper 2 cells respond differentially to chemokines. J. Immunol. 160 (1998) 550-554
35. Smee D.F., Bailey K.W., and Sidwell R.W. Treatment of lethal vaccinia virus respiratory infections in mice with cidofovir. Antiviral Chem. Chemother. 12 (2001) 71-76
36. Smee D.F., Bailey K.W., Wong M.-H., and Sidwell R.W. Effects of cidofovir on the pathogenesis of a lethal vaccinia virus respiratory infection in mice. Antiviral Res. 52 (2001) 55-62
37. Smee D.F., Bailey K.W., Wong M.-H., Wandersee M.K., and Sidwell R.W. Topical cidofovir is more effective than is parenteral therapy for treatment of progressive vaccinia in immunocompromised mice. J. Infect. Dis. 190 (2004) 1132-1139
38. Smee D.F., and Sidwell R.W. A review of compounds exhibiting anti-orthopoxvirus activity in animal models. Antiviral Res. 57 (2003) 41-52
39. Smee D.F., Sidwell R.W., Kefauver D., Bray M., and Huggins J.W. Characterization of wild-type and cidofovir-resistant strains of camelpox, cowpox, monkeypox, and vaccinia viruses. Antimicrob. Agents Chemother. 46 (2002) 1329-1335
40. Stittelaar K.J., van Amerongen G., Kondova I., Kuiken T., van Lavieren R.F., Pistoor F.H.M., Niesters H.G.M., van Doornum G., van der Zeijst B.A.M., Mateo L., Chaplin P.J., and Osterhaus A.D.M.E. Modified vaccinia virus ankara protects macaques against respiratory challenge with monkeypox virus. J. Virol. 79 (2005) 7845-7851
41. van den Broek M., Bachmann M.F., Köhler G., Barner M., Escher R., Zinkernagel R., and Kopf M. IL-4 and IL-10 antagonize IL-12-mediated protection against acute vaccinia virus infection with a limited role of IFN-γ and nitric oxide synthetase 2. J. Immunol. 164 (2000) 371-378